» Articles » PMID: 16904340

The Role of NK Cell Recognition of Nectin and Nectin-like Proteins in Tumor Immunosurveillance

Overview
Specialty Oncology
Date 2006 Aug 15
PMID 16904340
Citations 76
Authors
Affiliations
Soon will be listed here.
Abstract

Natural killer (NK) cells have important functions in the innate immunity to tumors. Recognition of tumor cells by NK cells is mediated by the interaction of activating and inhibitory NK cell receptors with ligands expressed on the tumor target. In addition, NK cell-target cell interactions require the engagement of adhesion molecules that stabilize the cell-cell conjugate. Recently, several novel NK cell receptors have been reported to regulate NK cell adhesion and activation through interaction with ligands of the nectin and nectin-like (Necl) family of adhesion molecules. We here review current knowledge on these receptors, CD226, CD96 and CRTAM, and their role in tumor immunosurveillance.

Citing Articles

Target therapy of TIGIT; a novel approach of immunotherapy for the treatment of colorectal cancer.

Sun J, Tian Y, Yang C Naunyn Schmiedebergs Arch Pharmacol. 2024; 398(1):231-241.

PMID: 39158733 DOI: 10.1007/s00210-024-03346-7.


A Machine Learning Model for the Prediction of COVID-19 Severity Using RNA-Seq, Clinical, and Co-Morbidity Data.

Sethi S, Shakyawar S, Reddy A, Patel J, Guda C Diagnostics (Basel). 2024; 14(12).

PMID: 38928699 PMC: 11202902. DOI: 10.3390/diagnostics14121284.


Genetic variability of three common NK and γδ T cell receptor genes (FCγ3R, NCR3, and DNAM-1) and their role in Polish patients with rheumatoid arthritis and ankylosing spondylitis.

Bialy S, Iwaszko M, Swierkot J, Kolossa K, Wielinska J, Jeka S Immunol Res. 2024; 72(4):614-625.

PMID: 38714580 PMC: 11347466. DOI: 10.1007/s12026-024-09488-3.


CD155-TIGIT Axis as a Therapeutic Target for Cancer Immunotherapy.

Mu Y, Guan X Curr Med Chem. 2024; 31(13):1634-1645.

PMID: 38666504 DOI: 10.2174/0929867330666230324152532.


Dysfunctional natural killer cells can be reprogrammed to regain anti-tumor activity.

Sabag B, Puthenveetil A, Levy M, Joseph N, Doniger T, Yaron O EMBO J. 2024; 43(13):2552-2581.

PMID: 38637625 PMC: 11217363. DOI: 10.1038/s44318-024-00094-5.